(Q37925028)

25 August 2017

0 references

1 reference

title

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. (English)

1 reference

25 August 2017

1 reference

1 reference

Mao Chen

1

1 reference

25 August 2017

Jia-Fu Wei

2

1 reference

25 August 2017

Yuan-Ning Xu

3

1 reference

25 August 2017

Xiao-Jing Liu

4

1 reference

25 August 2017

De-Jia Huang

5

1 reference

25 August 2017

publication date

30 May 2011

1 reference

Cardiovascular Therapeutics

25 August 2017

published in

1 reference

25 August 2017

volume

30

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

e227-33

1 reference

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00289.X

10.1111/J.1755-5922.2011.00289.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference